###begin article-title 0
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals
###end article-title 0
###begin p 1
Conceived and designed the experiments: HK BA MJD SKA. Performed the experiments: VM RJO JC WH KRP GC MJD. Analyzed the data: HK JC WH JD KRP GC RAC MJD SKA. Contributed reagents/materials/analysis tools: BA VM RJO JD RAC. Wrote the paper: HK MJD SKA. Contributed substantially to data analysis and preparation of manuscript: RAC GC KRP WH JC JD RJO VM BA. Contributed substantially to clinical cohort development and conceptual ideas: JD RJO VM BA. Made substantial contributions to experimental data and/or conceptual ideas: RAC GC KRP WH JC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 310 311 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 451 455 451 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 198 203 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 467 470 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 544 547 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Whether vexing clinical decision-making dilemmas can be partly addressed by recent advances in genomics is unclear. For example, when to initiate highly active antiretroviral therapy (HAART) during HIV-1 infection remains a clinical dilemma. This decision relies heavily on assessing AIDS risk based on the CD4+ T cell count and plasma viral load. However, the trajectories of these two laboratory markers are influenced, in part, by polymorphisms in CCR5, the major HIV coreceptor, and the gene copy number of CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine. Therefore, we determined whether accounting for both genetic and laboratory markers provided an improved means of assessing AIDS risk.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 336 347 336 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 589 590 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 766 777 766 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 952 953 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 586 589 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In a prospective, single-site, ethnically-mixed cohort of 1,132 HIV-positive subjects, we determined the AIDS risk conveyed by the laboratory and genetic markers separately and in combination. Subjects were assigned to a low, moderate or high genetic risk group (GRG) based on variations in CCL3L1 and CCR5. The predictive value of the CCL3L1-CCR5 GRGs, as estimated by likelihood ratios, was equivalent to that of the laboratory markers. GRG status also predicted AIDS development when the laboratory markers conveyed a contrary risk. Additionally, in two separate and large groups of HIV+ subjects from a natural history cohort, the results from additive risk-scoring systems and classification and regression tree (CART) analysis revealed that the laboratory and CCL3L1-CCR5 genetic markers together provided more prognostic information than either marker alone. Furthermore, GRGs independently predicted the time interval from seroconversion to CD4+ cell count thresholds used to guide HAART initiation.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 220 231 220 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 262 265 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The combination of the laboratory and genetic markers captures a broader spectrum of AIDS risk than either marker alone. By tracking a unique aspect of AIDS risk distinct from that captured by the laboratory parameters, CCL3L1-CCR5 genotypes may have utility in HIV clinical management. These findings illustrate how genomic information might be applied to achieve practical benefits of personalized medicine.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 907 910 907 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lederman1">[1]</xref>
###xml 1014 1017 1014 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Townson1">[2]</xref>
###xml 1019 1022 1019 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Menten1">[3]</xref>
###xml 1024 1027 1024 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Xin1">[4]</xref>
###xml 1029 1032 1029 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 1071 1072 1071 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 791 794 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 901 906 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 988 991 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1129 1132 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1142 1150 <span type="species:ncbi:9606">patients</span>
The last few years have witnessed an unprecedented interest and effort in identifying the genetic determinants that underlie susceptibility to human diseases. Concurrently there is strong interest in developing ways to use this genetic information to provide "individualized medicine", i.e., tailor the clinical care of patients according to specific elements of their genetic constitution that can convey independent predictive capacity with respect to disease prognostication. However, a framework of how to assess fully whether such genetic information might help improve the clinical management of patients remains unclear, especially when compared to laboratory markers that are considered the gold standard in evaluating disease prognosis. To address this gap in knowledge we used (i) HIV infection, (ii) variations in the genes encoding CC chemokine receptor 5 (CCR5), the major coreceptor for HIV-1 [1], and CC chemokine ligand 3-like 1 (CCL3L1), the most potent CCR5 agonist and HIV-suppressive chemokine [2], [3], [4], [5], and (iii) the laboratory markers (CD4+ T cell count and viral load) currently used to evaluate HIV-infected patients, as a model system.
###end p 9
###begin p 10
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 210 213 210 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dybul1">[6]</xref>
###xml 215 218 215 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Yeni1">[7]</xref>
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpaidsinfo.nih.gov1">[8]</xref>
###xml 225 228 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpwwwaidsinfo1">[9]</xref>
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 389 390 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 390 393 390 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dybul1">[6]</xref>
###xml 395 398 395 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Yeni1">[7]</xref>
###xml 400 403 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpaidsinfo.nih.gov1">[8]</xref>
###xml 405 408 405 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpwwwaidsinfo1">[9]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Holmberg1">[10]</xref>
###xml 505 509 505 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Cohen1">[11]</xref>
###xml 573 574 573 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 762 766 762 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Holmberg1">[10]</xref>
###xml 875 876 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1145 1146 1145 1146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1217 1218 1217 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1528 1529 1528 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1562 1566 1562 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hughes1">[12]</xref>
###xml 1568 1572 1568 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-1">[13]</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 450 453 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1069 1072 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-1-infected subjects are typically started on highly active antiretroviral therapy (HAART) when their CD4+ T cell count reaches a threshold below which their risk for developing AIDS increases significantly [6], [7], [8], [9]. These HAART-initiating CD4+ T cell count thresholds vary depending on the clinical and economic settings, but are typically between 200 and 350 CD4+ T cells/mm3[6], [7], [8], [9]. Nevertheless, when to initiate HAART in HIV-infected subjects remains a clinical dilemma [10], [11], especially when individuals present for clinical care with CD4+ T cell counts above 350. Those favoring early initiation cite, among other reasons, the risk that progressive immunologic damage will be incompletely reversible after initiation of HAART [10]. However, there are significant inter-subject differences in the rate at which individuals lose and gain CD4+ T cells before and after receipt of HAART, respectively. Consequently, identifying subjects who, despite HAART, are at greater risk of persistent immunologic damage, or predicting how soon an HIV-infected individual might arrive at a predetermined HAART-initiating CD4+ T cell count poses a diagnostic challenge. Furthermore, although a CD4+ T cell count and plasma viral load provides an excellent snapshot of the immunological and virological status of the infected host at the time of their clinical assessment, they are imperfect surrogates of AIDS risk. This is because both reside downstream of the causal pathways that mediate the extent of CD4+ cell loss and viral replication [12], [13], and hence, they do not have any inherent capacity to predict their future trajectory. This necessitates serial determinations of these biomarkers to assess AIDS prognosis.
###end p 10
###begin p 11
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dean1">[14]</xref>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Martin1">[15]</xref>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-OBrien1">[16]</xref>
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kaslow1">[17]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez2">[18]</xref>
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mangano1">[19]</xref>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-OBrien2">[21]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hunt1">[22]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Carrington1">[24]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Telenti1">[25]</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Douek1">[26]</xref>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kaufmann1">[27]</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Florence1">[28]</xref>
###xml 453 457 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Moore1">[29]</xref>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 561 562 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kaufmann1">[27]</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Moore1">[29]</xref>
###xml 637 641 637 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Grabar1">[30]</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Tarwater1">[31]</xref>
###xml 649 653 649 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hunt2">[32]</xref>
###xml 655 659 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Moore2">[33]</xref>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Valdez1">[34]</xref>
###xml 667 671 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Podlekareva1">[35]</xref>
###xml 788 789 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1340 1344 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpwww.clinicaltrials.gov1">[36]</xref>
###xml 332 335 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 603 606 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1016 1019 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The trajectories of CD4+ T cell counts before and during HAART are likely to be dependent on host-viral interactions [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26]. Additionally, during HAART these trajectories are also likely to depend in part on the regenerative capacity of the host as up to 30% of HIV-infected subjects have impaired recovery of CD4+ T cell counts, despite suppression of viral replication [27], [28], [29]. Additionally, a large proportion of patients who initiate therapy with a low CD4+ nadir (<200 cells/mm3) fail to normalize CD4+ counts, despite HIV-suppressive HAART [27], [29], [30], [31], [32], [33], [34], [35]. Thus, accounting for polymorphisms in host genes that participate in causal host-viral interactions that affect CD4+ T cell depletion before HAART and the immune reconstitution (i.e., recovery of CD4+ T cell numbers and function) during HAART might provide a measure of genetic risk that could aid in the clinical assessment and management of HIV-infected subjects. Conceivably, those subjects whose genetic constitution confers a greater risk of progressing rapidly to AIDS as well as impaired recovery during HAART might benefit from earlier initiation of therapy and possibly also from adjuvant therapies that promote immunological recovery (e.g. recombinant IL-7 [36]).
###end p 11
###begin p 12
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dean1">[14]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Martin1">[15]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-OBrien1">[16]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kaslow1">[17]</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez2">[18]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mangano1">[19]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-OBrien2">[21]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hunt1">[22]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 417 421 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Zimmerman1">[37]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-McDermott1">[38]</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hladik1">[39]</xref>
###xml 435 439 435 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Valdez2">[40]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hendrickson1">[41]</xref>
###xml 466 472 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 556 559 556 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Townson1">[2]</xref>
###xml 561 564 561 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 593 594 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 619 622 619 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ketas1">[42]</xref>
###xml 634 640 634 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 856 859 856 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Sadam1">[43]</xref>
###xml 867 871 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Nakajima1">[44]</xref>
###xml 954 957 954 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 959 963 959 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kuhn1">[45]</xref>
###xml 965 969 965 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-MeddowsTaylor1">[46]</xref>
###xml 1090 1091 1090 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1116 1119 1116 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 1121 1125 1121 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 1127 1131 1127 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kuhn1">[45]</xref>
###xml 1133 1137 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Shalekoff1">[47]</xref>
###xml 1208 1211 1208 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 1234 1235 1234 1235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1243 1244 1243 1244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1262 1266 1262 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Shalekoff1">[47]</xref>
###xml 1291 1292 1291 1292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1382 1386 1382 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 1416 1422 1416 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 1439 1443 1439 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 1657 1658 1657 1658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1678 1682 1678 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 2148 2152 2148 2152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 2175 2182 2175 2182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2327 2331 2327 2331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 2333 2337 2333 2337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kalish1">[48]</xref>
###xml 2339 2343 2339 2343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kniker1">[49]</xref>
###xml 2345 2349 2345 2349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Birx1">[50]</xref>
###xml 2351 2355 2351 2355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gordin1">[51]</xref>
###xml 2357 2361 2357 2361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan2">[52]</xref>
###xml 2363 2367 2363 2367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Maas1">[53]</xref>
###xml 2421 2425 2421 2425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3</italic>
###xml 2467 2470 2467 2470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 2480 2484 2480 2484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gibbs1">[54]</xref>
###xml 2615 2620 2615 2620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L</italic>
###xml 284 287 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 530 533 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 726 729 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 884 892 <span type="species:ncbi:9606">children</span>
###xml 916 921 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1087 1090 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1092 1097 <span type="species:ncbi:9606">women</span>
###xml 1218 1221 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1368 1371 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1522 1525 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1654 1657 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1878 1881 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2456 2466 <span type="species:ncbi:9598">chimpanzee</span>
###xml 2499 2504 <span type="species:ncbi:9606">human</span>
###xml 2635 2641 <span type="species:ncbi:9606">humans</span>
###xml 2650 2655 <span type="species:ncbi:9606">human</span>
In this study, we focused on evaluating the prognostication capacity of genetic variations in CCR5 and CCL3L1 vis-a-vis the laboratory markers for the following reasons. There is substantial data demonstrating that polymorphisms in CCR5 are associated with variable susceptibility to HIV, AIDS progression rates, and CD4+ T cell count recovery during HAART [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [37], [38], [39], [40], [41]. The copy number of CCL3L1 influences mRNA/protein expression levels of this potent HIV suppressive chemokine [2], [5] as well as proportion of CD4+ T cells expressing CCR5 [5], [42], and CCL3L1 gene dose has been associated with intersubject differences in (i) susceptibility to HIV acquisition in European-, African-, Hispanic-American adults, intravenous drug users from Estonia and hemophiliacs from Japan [5], [43], [44], as well as children exposed perinatally to HIV-1 from Argentina and South Africa [5], [45], [46]; (ii) viral load in different cohorts, including subjects who were recruited during acute/early infection as well as HIV+ women from South Africa [5], [20], [45], [47]; (iii) rates of progression to AIDS in European and African Americans [5]; (iv) HIV-specific CD4+ and CD8+ T cell responses [47]; and (v) recovery of CD4+ T cell counts in subjects who received HAART during chronic or acute/early HIV infection [23]. Additionally, we found that CCL3L1 copy number and CCR5 genotypes that were associated with reduced cell mediated immune responses in HIV-negative individuals of European descent were similar to those that were associated with a rapid rate of disease progression in HIV+ European Americans [20], suggesting that the CCL3L1-CCR5 axis might play an important role in mediating cellular immune responses relevant to AIDS pathogenesis. In the latter analyses, cell mediated immune responses in HIV-negative subjects was assessed by delayed type hypersensitivity (DTH) skin test reactivity following challenge with two separate antigens namely keyhole limpet hemocyanin and purified protein derivative, and concordant associations were observed with both antigens ([20]; DTH responses are an in vivo parameter of T cell and cell mediated immune responses, and the strength of DTH responses are an independent determinant of AIDS susceptibility [20], [48], [49], [50], [51], [52], [53]). Finally, the finding that copy number variation in CCL3-like genes is also present in chimpanzee [5], macaque [54] and other non-human primate species (our unpublished observations) suggests an evolutionarily conserved host defense function for CCL3L-like genes in humans and non-human primates.
###end p 12
###begin p 13
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 154 165 154 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 297 300 297 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 333 344 333 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 434 435 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 491 492 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 588 589 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 875 878 875 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 880 884 880 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 886 890 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 945 956 945 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1201 1205 1201 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 1207 1211 1207 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Deeks1">[55]</xref>
###xml 1350 1361 1350 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1506 1507 1506 1507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1521 1525 1521 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 1539 1543 1539 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 1614 1625 1614 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1654 1655 1654 1655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1749 1753 1749 1753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 451 456 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 994 999 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1147 1152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To evaluate the genotype-phenotype associations for the combined effects of variations in CCL3L1 and CCR5, we assigned subjects to low, moderate and high CCL3L1-CCR5 genetic risk groups (GRGs), defined according to different combinations of specific CCR5 polymorphisms and CCL3L1 gene copy number [5], [20]. A low, moderate and high CCL3L1-CCR5 GRG status was associated with a step-wise increase in susceptibility to depletion of CD4+ T cells during HIV-1 infection, as well as impaired CD4+ T cell recovery during HAART [20], [23]. The association between CCL3L1-CCR5 GRG status and CD4+ T cell loss and/or AIDS susceptibility was observed in two separate groups of subjects who were followed from the early stages of their infection within the context of a natural history cohort as well as in a separate cohort of subjects who were recruited during acute/early infection [5], [20], [23]. Furthermore, we observed an enrichment of protective CCL3L1-CCR5 genotypes in subjects from a natural HIV-1 history cohort who were AIDS-free for more than 10 years, as well as in individuals from two different cohorts who were categorized as spontaneous HIV-1 controllers, i.e., elite or viremic controllers [20], [55], further underscoring that these genetic factors might play an important role in restricting disease progression. The association between CCL3L1-CCR5 GRG status and immune recovery was assessed in subjects who received HAART during chronic infection using two separate phenotypic endpoints: CD4+ T cell count [23] and function [20], assessed by DTH skin test responses. Concordant associations between CCL3L1-CCR5 genotype and recovery of CD4+ T cell counts were also observed in subjects who received HAART during acute/early infection [23].
###end p 13
###begin p 14
###xml 44 57 44 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5 g</italic>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 264 275 264 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 558 562 558 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 782 786 782 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 883 894 883 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1033 1044 1033 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1099 1100 1099 1100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1232 1243 1232 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 297 300 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 692 697 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1179 1182 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1309 1312 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Collectively, these findings suggested that CCL3L1-CCR5 genetic markers may have dual prognostic capacities, i.e., for both CD4+ T cell loss and recovery. A possible role for these genetic markers in evaluation of AIDS risk was underscored by the observation that CCL3L1-CCR5 GRG status predicted HIV disease course independent of the viral load and CD4+ T cell count as well as other explanatory variables that were in themselves independent markers of disease progression (e.g., percent, nadir and cumulative CD4 cell counts, and DTH skin test reactivity) [20]. Notably, the latter associations were observed in two separate and large groups of subjects who within the context of a natural HIV-1 history cohort were followed prospectively from the early stages of their infection [20]. These findings suggested that there is a component of AIDS risk that is genetically-defined by CCL3L1-CCR5 genetic variations which may not be captured fully by the laboratory markers. The consistency of the disease-influencing associations for CCL3L1-CCR5 GRG status that were independent of viral load and CD4+ T cell count as well as other explanatory variables in two separate groups of HIV-positive subjects prompted us to examine whether CCL3L1-CCR5 genetic factors might have utility in the clinical management of HIV-infected subjects.
###end p 14
###begin p 15
###xml 4 15 4 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 109 120 109 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 724 725 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 906 907 906 907 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1030 1031 1030 1031 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1194 1205 1194 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1325 1336 1325 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 73 76 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 373 376 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 454 457 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 1145 1150 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
For CCL3L1-CCR5 GRG status to have utility in the clinical management of HIV, in addition to an influence of CCL3L1-CCR5 genotypes on CD4+ cell recovery during HAART, we surmised that the following four criteria would have to be met. First, the prognostic strength of the GRGs for rates of disease progression should be comparable to that of the CD4+ cell count and plasma HIV viral load, contemporary laboratory markers used to assess AIDS prognosis in HIV-positive patients. Second, GRG status should accurately predict an increased risk of developing or progressing rapidly to AIDS when the laboratory markers may fail to do so. Third, the AIDS risk conveyed by the laboratory and genetic markers together, namely the CD4+ T cell count plus viral load plus GRG status, should exceed that conveyed by the two laboratory markers, especially during the early stages of infection when subjects have high CD4+ T cell counts. Fourth, GRG status should serve as independent determinants of the time interval from seroconversion to CD4+ cell count thresholds that are used to guide initiation of HAART. Here, in a large, well-characterized cohort of HIV-1-infected subjects, we investigated whether CCL3L1-CCR5 GRG status met each of these criteria. The sum of our findings using different analytical approaches suggests that the CCL3L1-CCR5 GRG status meet these criteria. These findings have broader translational value as they indicate that AIDS risk is an individual characteristic that might be estimated with an increased level of confidence if one also considers the genetic make-up of the host.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Study cohort
###end title 17
###begin p 18
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 54 57 54 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 81 84 81 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez2">[18]</xref>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 481 484 481 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez2">[18]</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez3">[56]</xref>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez4">[57]</xref>
###xml 525 533 525 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s004">Table S1</xref>
###xml 561 562 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 1667 1670 1667 1670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 1672 1676 1672 1676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 1678 1682 1678 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 114 117 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 558 561 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
In this study, we used the copy number of CCL3L1 gene [5] and CCR5 genotype data [5], [18] from a cohort of adult HIV+ subjects followed at the Wilford Hall United States Air Force Medical Center (WHMC), San Antonio, TX. This prospective observational cohort is a component of the United States Military's Tri-Service AIDS Clinical Consortium (TACC) Natural History Study [20], [23]. The characteristics of the study subjects (n = 1,132) have been described extensively previously [5], [18], [56], [57] and are summarized in Table S1. The nature of the WHMC HIV+ cohort is such that both the seroconverting and seroprevalent groups of patients were followed prospectively from the time of their diagnosis during the early stages of their disease, albeit the approximate time of seroconversion was estimable only in the former group. However, consistent with this recruitment pattern during the early stages of their disease we found that the genotype-phenotype associations detected in these two groups of patients were very similar [20]. For this reason, in this study relevant findings detected in the seroconverters (n = 515) were validated in the seroprevalent (n = 617) component of the cohort. Forty percent of the entire cohort progressed to AIDS (1987 criteria), and 39% died during the study period that ended December 31, 1999. Thus, this cohort was well suited to evaluate our study questions/criteria because all subjects were prospectively followed from the early stages of their infection, and factors that may confound genotype-phenotype studies (e.g., unequal access to medical care and antiretroviral therapy, and loss to follow-up) were not present [5], [20], [23]. The voluntary, fully informed consent of the subjects used in this research was obtained as required by Air Force Regulation 169-9 and additional approval from the Institutional Review Board (IRB) of WHMC and the University of Texas Health Science Center, San Antonio, TX.
###end p 18
###begin title 19
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
CCL3L1-CCR5 Genetic Risk Groups
###end title 19
###begin p 20
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 25 28 25 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 126 137 126 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 214 218 214 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 222 229 222 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">non-det</sup>
###xml 208 229 208 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1<sup>high</sup>CCR5<sup>non-det</sup></italic>
###xml 248 252 248 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 256 259 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">det</sup>
###xml 242 259 242 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1<sup>high</sup>CCR5<sup>det</sup></italic>
###xml 270 273 270 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 277 284 277 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">non-det</sup>
###xml 264 284 264 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1<sup>low</sup>CCR5<sup>non-det</sup></italic>
###xml 302 305 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 309 312 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">det</sup>
###xml 296 312 296 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1<sup>low</sup>CCR5<sup>det</sup></italic>
###xml 369 372 369 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 489 500 489 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 558 559 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 656 659 656 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 555 558 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The copy number of CCL3L1[5] and CCR5 haplotype pairs were categorized into three risk categories, and we labeled a patients' CCL3L1-CCR5 genotype as a low, moderate or a high GRG. The prevalence of the low (CCL3L1highCCR5non-det), moderate (CCL3L1highCCR5det and CCL3L1lowCCR5non-det) and high (CCL3L1lowCCR5det) GRG in the WHMC cohort is 50, 42, and 8%, respectively [5], [20]. In some analyses, we combined the moderate and high GRG into a single category. Of the 1,132 study subjects, CCL3L1-CCR5 genotype data for this study was available from 1,103 HIV+ subjects and they were 624, 410 and 69 European-, African- and Hispanic-Americans, respectively [5].
###end p 20
###begin title 21
Clinical outcomes and laboratory parameters
###end title 21
###begin p 22
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dybul1">[6]</xref>
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Yeni1">[7]</xref>
###xml 172 175 172 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpaidsinfo.nih.gov1">[8]</xref>
###xml 177 180 177 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-httpwwwaidsinfo1">[9]</xref>
###xml 428 435 428 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Birx1">[50]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gordin1">[51]</xref>
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan2">[52]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan2">[52]</xref>
The outcomes analyzed were risk of development of AIDS, and rate of progression to AIDS as well as to CD4 cell count thresholds used to guide initiation of HAART [6], [7], [8], [9]. The 1987 Centers for Disease Control (CDC) criteria for AIDS were used in these studies. The laboratory variables studied were baseline CD4 cell counts, steady-state viral load, and DTH skin test responses. DTH responses reflects T cell function in vivo (e.g. IL-2 production) and is an independent predictor of disease outcome [20], [50], [51], [52]. Extensive details regarding the DTH testing are provided elsewhere [20], [52].
###end p 22
###begin p 23
###xml 24 28 24 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 30 34 30 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Silverberg1">[58]</xref>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
As described previously [20], [58], we accounted for possible receipt of anti-retroviral therapy (ART) by using the calendar year of membership in the cohort as a proxy for receipt of mono/dual therapy (1990-1996) and HAART (1996-onwards). All subjects who were recruited in the therapy eras were pooled into a single group [20]. The therapy eras and the number of subjects with cohort membership during each era are as described previously [20]. Predictably, membership of a subject to the era in which HAART was available was associated with a significantly reduced risk of progressing to AIDS [20].
###end p 23
###begin title 24
Statistical methods
###end title 24
###begin p 25
To address our study questions/criteria, we used the following statistical approaches.
###end p 25
###begin p 26
###xml 32 43 32 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gallagher1">[59]</xref>
###xml 599 600 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1462 1463 1458 1459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1459 1462 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
First, to determine whether the CCL3L1-CCR5 GRGs conveyed a reduced or increased AIDS risk in settings when the laboratory markers would have suggested an opposite risk, we employed the likelihood ratio (LR) statistic. We used this statistic as it more directly describes the effect of a test result (in this case GRG status) on the odds of disease [59]. LR estimates for the possibility of developing AIDS in the future based on the stratum of the laboratory markers as well as for the low, moderate and high GRGs. The stratum for the baseline CD4 cell counts were <350, 350-699, or >/=700 cells/mm3, and for the viral load they were < or >/=55,000 copies/ml. These cut-offs were based on published guidelines for assessing AIDS risk that were prevalent during the time these analyses were being conducted. LR was estimated as the ratio of the incidence of AIDS in subjects with a given GRG, CD4 or viral load stratum (i.e., post-test probability of developing AIDS in the study cohort based on the laboratory or genetic markers) and the overall incidence of AIDS in the entire cohort (i.e., pre-test probability of AIDS in the study cohort before accounting for the laboratory or genetic markers). Thus, the LR represents an altered risk in the possibility of developing AIDS in the future based on a subjects' GRG and specific stratum of CD4 or viral load (or the indicated combinations thereof) divided by the overall likelihood of developing AIDS in the HIV+ subjects in the WHMC cohort during the study period.
###end p 26
###begin p 27
Second, in addition to the LR, we also estimated the pre- and post-test probabilities of developing AIDS during the study period. The LR and probabilities of developing AIDS during the study period were assessed at two levels: we initially calculated LRs and the pretest probability for the laboratory and genetic markers separately (unstratified analysis), and then in the different CD4 and viral load strata in subjects with specific GRGs (stratified analyses).
###end p 27
###begin p 28
Third, using a Poisson regression model, we estimated the annual incidence of AIDS in the seroconverting component of the WHMC cohort according to a subjects' laboratory and genetic markers.
###end p 28
###begin p 29
###xml 442 443 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 449 450 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 604 605 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 607 608 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
Fourth, we derived an estimate of the number of subjects one would need to treat to prevent the occurrence of one case of AIDS (that is, the number-needed-to-treat, NNT). For this, we applied separate Poisson regression models to data from seroconverters who were recruited in eras when antiretroviral therapy (ART) was available (therapy era) or was not available (no therapy era). From these results, the NNT was calculated as follows: If In and It represent the estimated incidence of AIDS in the no therapy era (n) and therapy (t) era from the Poisson regression models, respectively, then NNT = 1/(In-It). The estimate of NNT obtained was then rounded to the nearest integer.
###end p 29
###begin p 30
###xml 583 584 583 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1445 1446 1443 1444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1504 1505 1500 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1547 1548 1541 1542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1732 1733 1724 1725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2052 2056 2044 2048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Langdorf1">[60]</xref>
###xml 2058 2062 2050 2054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lemon1">[61]</xref>
###xml 2064 2068 2056 2060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Li1">[62]</xref>
###xml 2070 2074 2062 2066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Province1">[63]</xref>
###xml 2076 2080 2068 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Vlahou1">[64]</xref>
###xml 2545 2552 2537 2544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s001">Text S1</xref>
###xml 2557 2566 2549 2558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s002">Figure S1</xref>
Fifth, we used two distinct yet complementary approaches to assess whether the GRGs provided additive value for prognostication of AIDS over and above that provided by the CD4 cell count and viral load. In the first approach, we used a risk scoring system based on cut-offs for CD4 cell counts and the viral load, and conducted survival analyses for time to AIDS. The cut-offs used were based on CD4 cell count and viral load thresholds at which one might consider initiation of therapy. In the risk scoring systems, the cut-offs for CD4 cell counts were at 200, 350 and 450 cells/mm3 and for the viral load it was at 55,000 copies/ml; a CD4 cell count of 450 cells/mm3 was used as a threshold to determine the relative prognostic value of the laboratory and genetic markers during the early stages of the infection and was an arbitrary cut-off used to reflect early stage disease. Kaplan Meier (KM) survival curves were constructed to graphically illustrate the rate of progression to AIDS, and the log-rank test was used for between-group analysis. We used Cox proportional hazards models to estimate the relative hazards (with 95% confidence intervals (CI)) after testing for the assumption of proportional hazards by plotting the Schoenfeld residuals. Schoenfeld residuals were calculated for each Cox proportional hazards model studied by using the Breslow-Peto approach. Model fit was assessed using the likelihood ratio chi-square (LR chi2) and Akaike information criterion (AIC). The critical chi2 was estimated by dividing the logrank chi2 by its degrees of freedom. The risk-scoring systems were first applied to the seroconverting component of the cohort and then for purposes of replication, we also estimated the LR chi2 and AIC estimates in the seroprevalent group of subjects in the WHMC cohort. In the second risk-scoring approach, we used the classification and regression trees (CART) that are commonly used as a method of deductive reasoning for the purposes of data mining and extracting relationships among the predictor variables [60], [61], [62], [63], [64]. The advantage of the CART approach is that the algorithm generates a decision-tree that is free of any preconceived bias with respect to predefined cut-offs for viral load and CD4 cell counts at which ART might be initiated. The decision tree generated by CART for risk of developing AIDS was then used to determine whether it also had applicability for stratifying the rate of progression to AIDS. Extensive details of the model are provided in Section 1 of the Text S1 and Figure S1.
###end p 30
###begin p 31
###xml 223 224 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Finally, KM survival curves were used to determine time-from-seroconversion to the CD4 cell count thresholds that might be used to decide when to initiate HAART. We used the thresholds of 200 and 350 as well as 450 cells/mm3. We used Stata 7.0 (Stata Corp., College Station, TX) software for all statistical analyses and the program DTREG (Brentwood, TN) for generation of the classification trees.
###end p 31
###begin title 32
Results
###end title 32
###begin p 33
###xml 65 76 65 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 118 121 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The four criteria that might provide a framework for considering CCL3L1-CCR5 GRG status in the clinical management of HIV-infected subjects were addressed as follows.
###end p 33
###begin title 34
Criterion one
###end title 34
###begin p 35
###xml 427 434 427 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 556 567 556 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 735 742 735 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 976 977 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 979 986 977 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 1119 1126 1117 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 315 321 <span type="species:ncbi:9606">person</span>
###xml 703 709 <span type="species:ncbi:9606">person</span>
To determine whether the genetic and laboratory markers had comparable prognostic capacities, we first conducted unstratified analyses in which we computed the probabilities and likelihood ratio (LR) of developing AIDS based on a subject's baseline CD4 or steady-state viral load stratum before accounting for that person's GRG. Similar estimates for the GRGs were computed before accounting for a subject's CD4 or viral load (Table 1). The pretest probability of developing AIDS in the entire cohort and the seroconverting component of the cohort in whom CCL3L1-CCR5 genotype was determined was 39% and 27%, respectively. However, the post-test probabilities of developing AIDS differed according to a person's GRG or CD4 cell count (Table 1). Notably, in the overall cohort, the posttest probabilities (parenthesis) for a low (32%), moderate (43%), and high (66%) GRG were similar to those for a baseline CD4 cell count of >/=700 (26%), 350-699 (40%) and <350 (61%) cells/mm3 (Table 1; values in parentheses denote the posttest probabilities, and for GRG status they are the estimates shown in the bottom-most row of Table 1, whereas for the CD4 cell count they are the estimates shown under the column "unstratified by GRG").
###end p 35
###begin title 36
###xml 120 131 120 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
The likelihood ratio (LR) and pre- and post-test probability of developing AIDS according to the laboratory markers and CCL3L1-CCR5 GRGs.
###end title 36
###begin p 37
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The unstratified analyses are posttest and LR estimates for the baseline CD4+ T cell count and steady-state viral load prior to accounting for a subject's GRG and are in the column denoted as "unstratified by GRG", whereas similar estimates for the GRGs before accounting for a subject's baseline CD4 cell count and steady-state viral load are in the bottom-most row.
###end p 37
###begin p 38
Data are for the entire cohort.
###end p 38
###begin p 39
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Data are for seroconverting subjects and indicates the steady-state viral load in these subjects. k, denotesx103 copies/ml.
###end p 39
###begin p 40
The percentages in the brackets [ ] denote the pre-test followed by the post-test probability of developing AIDS.
###end p 40
###begin p 41
###xml 235 242 235 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 336 343 336 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 571 572 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 649 656 647 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 895 902 891 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
A LR of >1 or <1 indicates a greater or lower likelihood of developing AIDS, respectively, and we found that the three CD4 and viral load strata as well as a low, moderate and high GRG status were each associated with predictable LRs (Table 1). For example, LRs for a low, moderate and high GRG were 0.73, 1.16, and 3.02, respectively (Table 1, bottom-most row). The LR estimates for a low, moderate and high GRG were quantitatively very similar to the LRs (estimates in parenthesis) for a baseline CD4 cell count of >/=700 (0.55), 350-699 (1.04) and <350 (2.44) cells/mm3 (the latter estimates are in the column denoted as "unstratified by GRG" in Table 1). Similarly, the LR (parenthesis) for a low (0.73) and high (3.02) GRG were similar to those for a viral load of <55,000 (0.74) and >/=55,000 (2.22) copies/ml, respectively (the latter estimates are in the column "unstratified by GRG" in Table 1). Thus, the results of these unstratified analyses indicated that the posttest probabilities and LR estimates of developing AIDS associated with a low, moderate or high GRG were remarkably similar to those conveyed by strata of laboratory markers that are known to prognosticate a low, moderate or high risk of AIDS.
###end p 41
###begin title 42
Criterion two
###end title 42
###begin p 43
###xml 517 524 517 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 786 793 786 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 879 880 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1040 1047 1040 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 1352 1353 1352 1353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
However, because a low, moderate and high GRG status associate with different degrees of CD4 cell loss and viral replication, an argument could be made that the GRGs do not add any additional prognostic information than that conveyed by the laboratory markers. Thus, we sought to determine whether GRG status predicted risk of AIDS when the CD4 and viral load may not. For this, we conducted stratified analyses in which we computed the LRs for the CD4 and viral load strata but after accounting for a subject's GRG (Table 1, columns under "stratified by GRG"). Three examples are used to illustrate that GRG staus accurately conveyed a reduced or increased AIDS risk, even in instances when the laboratory markers in themselves would have predicted a contrary risk of developing AIDS (Table 1). First, the LR and posttest probability values for a CD4 cell count of <350 cells/mm3 were 2.44 and 61%, respectively, but for a low, moderate, or high GRG in this CD4 strata they were 0.69 and 52%, 1.01 and 62%, and 13.3 and 95%, respectively (Table 1, top row). Hence, among subjects in whom a low CD4 count predicted an increased likelihood of developing AIDS, a low GRG tracked a subset of these subjects who have a lower risk of developing AIDS, whereas a high GRG identified a subset of individuals in this vulnerable CD4 cell stratum of <350 cells/mm3 who have an even higher risk of developing AIDS.
###end p 43
###begin p 44
###xml 86 87 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 252 259 250 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
###xml 599 600 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 787 794 783 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Table 1</xref>
Second, the LR and posttest probability values for a CD4 cell count of >/=700 cells/mm3 were 0.55 and 26%, respectively; but for a low, moderate, or high GRG within this CD4 stratum they were 0.70 and 20%, 1.35 and 32%, and 2.40 and 46%, respectively (Table 1). In this instance, among subjects in whom a high CD4 count would have predicted a lower likelihood of developing AIDS, a high and moderate GRG identified subsets of subjects with increased likelihoods of developing AIDS. Third, in the seroconverting subjects, the LR and posttest probability values for a CD4 cell count of >/=350 cells/mm3 and a viral load of <55,000 copies/ml were 0.64 and 19%; these values were 0.70 and 14%, 1.27 and 23%, and 3.28 and 43% for those assigned to a low, moderate, or high GRG, respectively (Table 1, estimates shown under row entitled "CD4 plus viral load"). Results of these analyses indicated that knowledge of the CCL3L1-CCR5 GRG status may improve the ability to predict AIDS risk, especially by identifying those subjects whose CD4 and viral load parameters may incorrectly predict a contrary risk of developing AIDS.
###end p 44
###begin title 45
Criterion three: approach #1 - risk-scoring systems
###end title 45
###begin p 46
###xml 225 232 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t002">Table 2</xref>
###xml 491 498 491 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t002">Table 2</xref>
###xml 744 745 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 791 798 789 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t002">Table 2</xref>
###xml 984 991 982 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t002">Table 2</xref>
###xml 1189 1196 1187 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t002">Table 2</xref>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
###xml 956 963 <span type="species:ncbi:9606">patient</span>
To determine whether GRG status added to the prognostic capacity of the CD4 cell count and viral load in predicting the risk of developing AIDS in seroconverters, the CD4 cell count and viral load were stratified as shown in Table 2. Predictably, the incidence of AIDS was much greater in those subjects whose membership in the cohort did not coincide with the therapy era (range: 4.3 to 52.3) than in those whose membership in the cohort coincided with the therapy era (range: 1.1 to 19.6; Table 2). However, irrespective of therapy eras, within each CD4/viral load stratum, low, moderate and high GRG status conveyed a step-wise increase in AIDS risk, which was also evident among subjects with the lowest risk CD4 cell count (>/=700 cells/mm3) and viral load (<20,000 copies/ml) profile (Table 2). Based on these analyses, we determined the number of patients that one would need to treat with HAART to prevent one case of AIDS if the GRG status of the patient were accounted for (Table 2). These analyses suggested that in each CD4/viral load stratum, compared to those with a high GRG, twice the number of subjects with a low GRG would need to be treated to prevent one case of AIDS (Table 2).
###end p 46
###begin title 47
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 130 141 130 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
Annual incidence of AIDS (%) and numbers needed-to-treat according to baseline CD4+ T cell count, the steady-state viral load and CCL3L1-CCR5 GRG, based on Poisson regression model.
###end title 47
###begin p 48
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
Results are from the seroconverting component of the cohort. CD4 cell count (baseline) is in cells/mm3. k, denotesx103 copies/ml. The assignment of subjects whose membership in the WHMC cohort fell in the eras in which HAART was available or not, and the impact of the HAART era on rates of disease progression are as described previously [20].
###end p 48
###begin p 49
###xml 116 127 116 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1057 1058 1055 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1060 1081 1058 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1A, and B to E</xref>
###xml 1144 1145 1142 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1194 1195 1192 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1197 1217 1195 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1A and F to I</xref>
###xml 1284 1285 1282 1283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1343 1344 1341 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1346 1366 1344 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1A and J to M</xref>
###xml 1488 1489 1486 1487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 183 186 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The preceding findings underscored that over and above the AIDS risk conveyed by the CD4 cell count and viral load, CCL3L1-CCR5 GRG status may serve as a unique parameter to identify HIV-infected individuals who are at an increased risk of developing AIDS. To investigate further this possibility, we considered whether GRGs and laboratory markers can be combined in a clinically meaningful way to enhance AIDS prognostication. As risk scoring systems have an inherent ease of applicability in a clinical setting, we used this as an approach to evaluate whether the prognostic value of GRGs might have value in clinical practice. We determined whether a three-pronged risk-scoring system that included the two laboratory markers and GRG status was superior in fractionating the risk of progressing rapidly to AIDS when compared to a two-pronged risk-scoring system that excluded GRG status. The first scoring system stratified the seroconverting component of the cohort into two groups based on whether their baseline CD4 cell count was < or >/=200 cells/mm3 (Figure 1A, and B to E); the second scoring system used a CD4 cut-off of 450 cells/mm3 but excluded the subjects with <200 CD4-cells/mm3 (Figure 1A and F to I); and the third scoring system also used a cut-off of 450 cells/mm3 but excluded those with a CD4 cell count of <350 cells/mm3 (Figure 1A and J to M). By excluding subjects with CD4 counts of <200 or <350 and by placing the upper CD4 cell count threshold at 450 cells/mm3, the second and third risk-scoring systems offered the opportunity to explore whether GRG status can prognosticate AIDS risk during the earlier stages of the disease, i.e., when the baseline CD4 cell count is higher.
###end p 49
###begin title 50
###xml 30 41 30 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
Prognostic performance of the CCL3L1-CCR5 GRGs in risk-scoring systems.
###end title 50
###begin p 51
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 422 423 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 511 512 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 195 198 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Panel A shows the three risk-scoring systems based on baseline CD4+ T cell counts (C), viral load (V) and GRGs (G) in the seroconverting and separately in the seroprevalent component of the WHMC HIV+ cohort. Panels B-C, F-G and J-K depict Kaplan Meier (KM) plots for progression to AIDS (1987 criteria) before and after accounting for the GRGs in the risk-scoring systems indicated on the left axis. The critical ratio chi2 values are indicated within the KM plots. Panels D, H and L depict likelihood ratio chi2 and AIC estimates in seroconverters, and panels E, I and M depict the same estimates for the seroprevalent subjects.
###end p 51
###begin p 52
###xml 50 86 50 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, B to D, F to H, and J to L</xref>
###xml 404 424 404 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, E, I and M</xref>
###xml 793 794 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 921 922 917 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1054 1055 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1111 1141 1105 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, panels D&#8211;E, H&#8211;I, L&#8211;M</xref>
In each of the three risk-scoring systems tested (Figure 1, B to D, F to H, and J to L), the prognostic performance of the nested models and survival curves that contained GRG status along with the CD4 and viral load (i.e., C+V+G) were superior to those risk-scoring systems that excluded the GRGs (i.e., C+V). Concordant effects of the GRGs were also found in the seroprevalent component of the cohort (Figure 1, E, I and M). The additive prognostication conveyed by the GRGs was indicated by (i) the Kaplan-Meir (KM) plots in which the disease-modulating effects of the GRGs were accounted for displayed improved stratification for different rates of disease progression than those plots in which only the effects of CD4 cell count and viral load were accounted for; (ii) higher critical chi2 values for the Cox models that contained the GRGs (values are in the panels depicting the KM plots; e.g., compare critical chi2 of 0.84 and 10.05 in panels J and K in models lacking and containing the GRGs, respectively); and (iii) higher likelihood ratio chi2 and lower AIC values in models that included the GRGs (Figure 1, panels D-E, H-I, L-M).
###end p 52
###begin p 53
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 204 251 204 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, compare panel B versus panels F and J</xref>
###xml 375 376 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 449 450 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 452 469 450 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, D and E</xref>
###xml 567 568 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 570 593 568 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, H, I, L and M</xref>
###xml 690 691 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 746 769 742 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1, H, I, L and M</xref>
The KM plots showed that the CD4 cell count and viral load provided the most prognostication only in the first scoring system, i.e., when subjects with a CD4 of <200 cells/mm3 were included in the model (Figure 1, compare panel B versus panels F and J). Supporting this, the prognostic capacity of the CD4 cell count as reflected by the estimates for the likelihood ratio chi2 and AIC were most apparent in subjects with a CD4 count of <200 cells/mm3 (Figure 1, D and E), but negligible in the other two scoring systems in which the CD4 cell counts were >200 cells/mm3 (Figure 1, H, I, L and M). Notably, in the second and third risk-scoring systems, the values for the likelihood ratio chi2 and AIC were similar for the viral load and the GRGs (Figure 1, H, I, L and M), suggesting that the prognostic information conveyed by the viral load and GRG status in these two risk-scoring systems were comparable.
###end p 53
###begin title 54
Criterion three: approach #2 - CART analysis
###end title 54
###begin p 55
###xml 211 212 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 557 566 555 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2A</xref>
###xml 571 580 569 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s002">Figure S1</xref>
###xml 775 784 773 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2A</xref>
###xml 789 799 787 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s002">Figure S1A</xref>
###xml 901 902 899 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1036 1037 1034 1035 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1039 1048 1037 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1A</xref>
###xml 1132 1141 1130 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2A</xref>
###xml 1146 1156 1144 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s002">Figure S1A</xref>
###xml 1375 1383 1373 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t001">Tables 1</xref>
###xml 1388 1389 1386 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003165-t002">2</xref>
###xml 1394 1402 1392 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1</xref>
###xml 1521 1537 1519 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2A and 2B</xref>
The predefined cut-offs for CD4 cell counts and the viral load in a risk-scoring system is useful because they reflect thresholds currently used to decide the initiation of HAART (e.g., CD4</=200 or 350 cells/mm3). However, the use of these cut-offs has the limitation of potentially biasing the risk-scoring system towards an improved discrimination of AIDS risk. For this reason, we used an additional approach to address criterion 3 and assessed the role of the GRGs in AIDS prognostication by using a classification and regression tree (CART) approach (Figure 2A and Figure S1). Based on the differential risk of developing AIDS, CART analysis identified a decision tree defined by four nodal points that stratified the cohort into five groups, denoted as groups A to E (Figure 2A and Figure S1A). Interestingly, the most proximal node defined by CART analysis was a CD4-cell count of 453 cells/mm3, which was similar to the CD4 cell count threshold we used in the aforementioned analyses in risk-scoring systems (i.e., 450 cells/mm3, Figure 1A). Additional nodes included the GRG and steady-state viral load of these subjects (Figure 2A and Figure S1A). In this instance, the nodal split for viral load defined by CART analysis was at 55,500 copies/ml, and this was similar to the cut-off for viral load that we used in the analyses shown above (i.e., 55,000 copies/ml; Tables 1 and 2 and Figure 1). The manner in which these splits stratified subjects with variable risks of AIDS development at each node is shown (Figure 2A and 2B).
###end p 55
###begin title 56
###xml 90 91 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Classification trees and their application in the seroconverting component of the WHMC HIV+ cohort.
###end title 56
###begin p 57
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 435 436 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 872 881 872 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2F</xref>
###xml 1665 1666 1665 1666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 2484 2485 2478 2479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 213 216 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) A binary decision tree derived by CART analysis for the risk of developing AIDS (1987 criteria) based on baseline CD4+ T cell counts, viral load (VL) and GRG status in the seroconverting component of the WHMC HIV+ cohort. The analysis identified five exclusive groups designated as Groups A to E. The tree shows that the proximal split was based on the CD4 cell count, and the CART analysis generated the cut-off to be 453 cells/mm3. The next split was based on a viral load of 17,500 copies/ml. The third split was based on GRG status, followed by another split at a viral load of 55,500 copies/ml. The five groups generated are color-coded and the number of subjects in each of these groups is shown along with their proportion in the study group. The values in brackets ([ ]) indicate the relative hazard estimates corresponding to each of these groups as shown in Figure 2F. (B) Pie charts depicting the proportion of subjects in each of the splits who did or did not develop AIDS (1987 criteria). Within each pie-chart, the dark pie-slice represents the proportion of subjects who developed AIDS. Yes and no refers to whether a subject does or does not categorize, respectively, to the indicated node. (C) KM plots for the rate of progression to AIDS from time of seroconversion based on the split at each corresponding node in the decision tree shown in panel A. The significance values shown below each KM plot were estimated using the logrank test. (D-F) Association between the five risk groups (panel D) generated by CART and the risk (panel E) and rate of developing AIDS (panel F). Panel D defines the risk groups based on the baseline CD4 (cells/mm3), steady state viral load (k, x1,000 copies/ml), and GRG status (M/H, moderate or high GRG; Low, low GRG). Gp, group. Panel E shows the probability (Prob) of developing AIDS within each risk group generated by CART analysis. "Overall" refers to the probability of developing AIDS in the seroconverting component of the cohort without accounting for the laboratory or genetic markers. DeltaP, change in probability from the overall probability. Panel F shows the KM plots for rate of progression to AIDS for the five groups of subjects identified by CART. The table to the right shows the relative hazards (RH) corresponding to these five groups estimated by using Cox proportional hazards models. In these analyses, the reference category (RH = 1) is group B, which denotes subjects that have a CD4 of >/=453 cells/mm3 and a viral load of <17,500 copies/ml. The results show that relative to this reference category, groups A, C and E are associated with a significantly increased risk of progressing rapidly to AIDS. (G-I) Similar analyses to those shown in panels D to F but using risk groups in which the GRGs are not included as prognosticators. In these analyses, the risk groups A and B shown in panel A and panel D were used along with two new groups designated as group F and group G. The latter two groups were derived from the Groups C to E shown in panel D by not accounting for the GRG status and dichotomizing the cohort further based on a viral load cut-off of 55,500 copies/ml. Reference category (RH = 1) is group B. In panels E and H, prob refers to probability.
###end p 57
###begin p 58
###xml 212 221 212 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2C</xref>
###xml 358 367 358 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2C</xref>
To assess if the nodal splits derived based on differential risk of AIDS development also conveyed differential rates of disease progression, we plotted KM plots for each binary split shown in the decision tree (Figure 2C). We observed that each nodal split was also associated with statistically significant differences in the rates of progression to AIDS (Figure 2C).
###end p 58
###begin p 59
###xml 22 31 22 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2D</xref>
###xml 130 139 130 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2E</xref>
###xml 182 191 182 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2F</xref>
###xml 386 387 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 613 614 607 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 749 758 743 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2F</xref>
###xml 949 950 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1008 1017 1002 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2F</xref>
The five risk groups (Figure 2D) defined by the CART analysis displayed strikingly different risks of future development of AIDS (Figure 2E) as well as rates of disease progression (Figure 2F). Compared to the pretest probability of developing AIDS in the overall seroconverting component of the cohort (27%), Group C, which is defined by individuals with a CD4 count of >/=453 cells/mm3, a viral load of >/=17,500 copies/ml, and moderate or high GRG status, was associated with a 25% excess probability of developing AIDS. By contrast, group B (subjects with a relatively high baseline CD4 count (>/=453 cells/mm3) and low steady-state viral load (<17,500 copies/ml)) was associated with a 15% reduced probability of developing AIDS in the future (Figure 2F). Cox proportional hazards modeling demonstrated that Group C was associated with the fastest rate of progression to AIDS, whereas group B (subjects with a CD4 cell count of <453453 cells/mm3) was associated the slowest rate of disease progression (Figure 2F).
###end p 59
###begin p 60
###xml 283 292 283 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2G</xref>
###xml 348 357 348 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2D</xref>
###xml 372 381 372 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2G</xref>
###xml 566 601 566 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2, E versus H and F versus I</xref>
###xml 795 796 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 836 837 822 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 864 873 850 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2F</xref>
###xml 878 879 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 900 901 882 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
To validate that GRG status provided additional predictive value in the decision tree, we excluded GRG status from the analysis, and determined the risk and rate of progressing to AIDS for the four risk groups defined by the CD4 cell count and viral load cut-offs generated by CART (Figure 2G). A comparison of the identical analyses for the five (Figure 2D) versus four (Figure 2G) risk groups revealed that inclusion of GRG status within the stratification schema provided more a refined risk-profile than a stratification schema that excluded GRG status (compare Figure 2, E versus H and F versus I). The overall discriminatory power for prognosticating subjects with differential rates of progression to AIDS was improved by approximately29% when the GRGs were included for prognostication (P = 0.0002; also compare the log-rank chi2 values in the KM plots in Figure 2F (chi2 = 60.35) and 2I (chi2 = 46.78), showing higher values when GRG status is included in the model).
###end p 60
###begin p 61
###xml 16 24 16 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2</xref>
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 171 180 171 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s003">Figure S2</xref>
###xml 251 260 251 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figures 1</xref>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">2</xref>
###xml 272 281 272 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s003">Figure S2</xref>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 474 485 474 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 618 619 618 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 319 322 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The analyses in Figure 2 are for the seroconverting component of the WHMC HIV+ cohort, and we replicated these observations in the seroprevalent component of this cohort (Figure S2). Hence, the findings of two distinct risk-stratification approaches (Figures 1 and 2, and Figure S2) in two large and separate groups of HIV+ subjects demonstrated that the GRGs improve the ability to capture the wide spectrum of AIDS risk. Remarkably, the CART approach also showed that the CCL3L1-CCR5 GRGs assist in AIDS prognosis mainly during early-stage disease, such as when baseline CD4 cell counts are greater than 453 cells/mm3, a CD4 cell count threshold that is well above the point at which ART is currently recommended.
###end p 61
###begin title 62
Criterion four
###end title 62
###begin p 63
###xml 396 399 396 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Yeni1">[7]</xref>
###xml 845 854 845 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g003">Figure 3A</xref>
###xml 983 984 983 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1036 1053 1036 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g003">Figure 3A, middle</xref>
###xml 159 162 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 801 809 <span type="species:ncbi:9606">patients</span>
The aforementioned findings indicated that along with the CD4 cell count and viral load, the GRGs provided additive prognostication during the early stages of HIV infection, implying that the GRGs might prognosticate the time-interval from seroconversion to arrival at CD4 cell count thresholds relevant to commencing therapy. Given the uncertainty surrounding the optimal time to initiate HAART [7] as well as the results of our CART analysis, we chose three CD4 cell count cut-offs to reflect early (450 to approximate the 453 cut-off defined by CART analysis), intermediate (350), and late (200) HAART-initiating CD4 cell count thresholds. These analyses revealed that there was a step-wise increase in the time-interval from seroconversion to arrival at each of these CD4 cell count thresholds in patients with a high, moderate and low GRG (Figure 3A). Thus, it took nearly twice as long for subjects with a low GRG status to arrive at a CD4 cell count threshold of <350 cells/mm3 than subjects with a high GRG (5.48 vs 2.68 years; Figure 3A, middle).
###end p 63
###begin title 64
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
CCL3L1-CCR5 GRGs influence median time-from-seroconversion to CD4 cell count thresholds that might be used to guide initiation of HAART, and time from a high to a low CD4 cell count.
###end title 64
###begin p 65
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 533 534 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 736 737 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 824 825 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</italic>
###xml 940 942 892 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 990 991 942 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
In Panel A, KM plots show the time-from-seroconversion to arrival at <450 (left), <350 (center) or <200 (right) CD-cells/mm3. In Panel B, the KM plots are for progression from <450 to <200 CD4-cells/mm3 in all seroconverters (left) or seroconverters recruited and followed during the years 1990 to 1999, a time-period in which antiretroviral therapy was available (right). The color codes for the KM plots in panel B are: blue, low GRG; brown, moderate and high GRGs combined into a single category; and black, all subjects. Overall P values are at the top of each plot. Color-coded numbers at the upper right of the KM plots represent the median time-to-event, that is, from seroconversion to the indicated CD4 cell count. In panel A, P values for differences in median time-to-event relative to those with a low GRG were: *, 0.1131; dagger, 0.0089; double dagger, 0.0030; section sign, 0.0005; paragraph sign, 0.0001; and parallel, 9.6x10-7. RH, relative hazard; CI, confidence interval. P values in Panel B are adjusted for the steady-state viral load, baseline CD4 and best DTH response recorded during disease course, and subjects with a moderate or high GRG were combined into a single category.
###end p 65
###begin p 66
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 281 282 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 308 317 308 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g003">Figure 3B</xref>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 759 775 759 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g003">Figure 3B, right</xref>
Among seroconverting subjects who had <450 CD4 cells/mm3, the mean CD4 cell counts did not differ according to a subjects' GRG (mean in different GRGs was 375-383 cells/mm3). However, those with a low GRG status took nearly seven years longer to progress from <450 to <200 cells/mm3 than all other subjects (Figure 3B). The difference in the rate of progression from <450 to <200 cells/mm3 between those who were or were not assigned to a low GRG remained significant even after adjustment for the baseline CD4 cell count and viral load, the best DTH skin test reactivity recorded during disease course, and cohort membership in the calendar years 1990-1999, a time-period during which most of the AIDS events in this cohort occurred and HAART was available (Figure 3B, right).
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 518 519 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 170 175 <span type="species:ncbi:9606">human</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 264 269 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 368 371 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 702 709 <span type="species:ncbi:9606">persons</span>
###xml 761 764 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In this study, we tested the hypothesis that in conjunction with laboratory markers currently used to assess AIDS risk, the complex patterns of genetic variations in the human genome may have utility as tools for improved risk assessment of patients infected with HIV-1. The results of this study conducted in a large, and well-characterized natural history cohort of HIV-infected individuals indicate that in addition to the traditional markers of vulnerability (baseline CD4+ T cell count, viral load and rate of CD4+ T cell decline), the inclusion of a measure of genetic risk might offer an adjunctive, and complementary risk-stratification tool that may provide an improved method for identifying persons at high risk for future AIDS related events. These HIV vulnerable individuals may be ideal candidates for preventive AIDS care such as a closer follow-up, and potentially, earlier initiation of HAART. This inference is based on the following four principal findings.
###end p 68
###begin p 69
First, the predictive capacities of a low, moderate and high GRG for risk of developing AIDS, as estimated by the likelihood ratio, were equivalent to those of the strata of the laboratory markers that were associated with a low-, moderate- and high-risk of developing AIDS.
###end p 69
###begin p 70
Second, although the GRGs and the viral load had similar capacities for risk prognostication, GRG status was not a surrogate marker for the viral load. Instead, GRG status by consistently tracking individuals with reduced or increased likelihoods of developing AIDS provided prognostic information even in those instances when the laboratory markers predicted a contrary likelihood of developing of AIDS. Thus, the GRGs provided prognostic information with three unique characteristics, (i) independence from the AIDS risk conveyed by the viral load and CD4 cell count; (ii) equivalence in magnitude to the laboratory markers; and (iii) ability to correctly predict AIDS risk in spite of contrary information imparted in some instances by the viral load and CD4 cell count.
###end p 70
###begin p 71
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 518 519 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Third, the results from several complementary but distinct approaches demonstrated that the genetic and laboratory markers provide additive prognostic information that gauges the continuum of the risk of AIDS and disease progression more accurately than either marker alone. Importantly, the additive predictive capacity of the GRGs was evident during the early stages of the infection such as when the CD4 cell count was greater than 450 cells/mm3. It is especially noteworthy that in subjects with CD4>/=453 cells/mm3 and viral load of >/=17,500 copies/ml (approximately15% of the study cohort), a moderate or high GRG status was associated with a nearly seven-fold increased risk of progressing rapidly to AIDS.
###end p 71
###begin p 72
###xml 8 19 8 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Fourth, CCL3L1-CCR5 GRG status served as an independent determinant of how quickly HIV-infected subjects progressed to thresholds of CD4 cell counts that are currently used to decide when to initiate HAART. As a general rule, subjects with a moderate or high GRG progressed to these HAART-initiating CD4 cell count thresholds two to three times faster than those with a low GRG.
###end p 72
###begin p 73
###xml 104 115 104 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 722 723 722 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Douek1">[26]</xref>
###xml 787 791 787 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Zhang1">[65]</xref>
###xml 793 797 793 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mellors1">[66]</xref>
###xml 799 803 799 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lifson1">[67]</xref>
###xml 1191 1195 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 1209 1213 1197 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 756 759 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 900 903 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Genetic risk stratification of HIV-infected patients is especially attractive for three reasons. First, CCL3L1-CCR5 genotypes are not only independent determinants of disease, but more importantly, they are also capturing different aspects of AIDS risk than the traditional components of AIDS risk reflected in the laboratory markers currently used to assess disease status. Second, the time-insensitive nature of the genetic markers and the capacity of the GRGs to assess genetically-defined AIDS risk, especially during the proximal stages of infection, is appealing because there is substantial data suggesting that it is the magnitude of early immune damage that dictates, in part, steady-state viral load, initial CD4+ loss, and subsequently, pace of HIV disease course [20], [26], [65], [66], [67]. Third, the prevalence of the genetic factors that we have identified in a U.S.-based cohort of HIV-positive individuals (prevalence of the low, moderate and high GRGs is approximately50, 42 and 8%, respectively) is large enough to be of clinical relevance as these genetic factors can provide dual prognostication: risk of AIDS and disease progression, and recovery of CD4 cell numbers [23] and function [20] during HAART.
###end p 73
###begin p 74
###xml 48 59 48 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 518 526 518 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g001">Figure 1</xref>
###xml 538 546 538 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g002">Figure 2</xref>
###xml 681 689 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003165.s004">Table S1</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 879 890 879 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 985 994 985 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g003">Figure 3A</xref>
###xml 1093 1094 1093 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1096 1105 1096 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003165-g003">Figure 3B</xref>
The robustness of the associations detected for CCL3L1-CCR5 GRG status is suggested by several observations. First, concordant results were obtained when using different analytical approaches and when using a stringent clinical phenotypic endpoint namely AIDS (1987 CDC criteria). The finding that the copy number of CCL3L1 and CCR5 genotypes together provided prognostication during the early stages of the disease (CD4 cell counts of >450 cells/mm3) was detected using two separate approaches: risk-scoring systems (Figure 1) and CART (Figure 2). Additionally, consistent results for the latter two analyses were observed in two separate groups of subjects from the same cohort (Table S1), both of whom were followed prospectively from the early stages of their infection [20]. Furthermore, concordant results were obtained when the survival curves for the association between CCL3L1-CCR5 GRGs were computed from either time-of-seroconversion to different CD4 cell count thresholds (Figure 3A) or from one CD4 cell count threshold to another (i.e., progression from <450 to <200 CD4-cells/mm3; Figure 3B), and the latter associations remained consistent after adjustment for other explanatory variables known to influence disease progression rates.
###end p 74
###begin p 75
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez2">[18]</xref>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez3">[56]</xref>
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 277 280 277 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 612 618 612 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 697 700 697 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Sadam1">[43]</xref>
###xml 708 712 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Nakajima1">[44]</xref>
###xml 714 718 714 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kuhn1">[45]</xref>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-MeddowsTaylor1">[46]</xref>
###xml 823 827 823 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 920 932 920 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5 HHE/HHE</italic>
###xml 937 946 937 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HHC/HHG*2</italic>
###xml 971 975 971 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Martin1">[15]</xref>
###xml 977 981 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kaslow1">[17]</xref>
###xml 983 987 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez2">[18]</xref>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mangano1">[19]</xref>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hladik1">[39]</xref>
###xml 1090 1094 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 1142 1150 1142 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5-HHE</italic>
###xml 1166 1169 1166 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HHC</italic>
###xml 1173 1178 1173 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HHG*2</italic>
###xml 1212 1216 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Hladik1">[39]</xref>
###xml 1218 1222 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mummidi1">[68]</xref>
###xml 1224 1228 1224 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Thomas1">[69]</xref>
###xml 1230 1234 1230 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Salkowitz1">[70]</xref>
###xml 1236 1240 1236 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Kawamura1">[71]</xref>
###xml 1317 1321 1317 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Thomas1">[69]</xref>
###xml 1323 1327 1323 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Reynes1">[72]</xref>
###xml 1340 1344 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Reynes2">[73]</xref>
###xml 1372 1376 1372 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Reynes3">[74]</xref>
###xml 1408 1412 1408 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gervaix1">[75]</xref>
###xml 1414 1418 1414 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Vincent1">[76]</xref>
###xml 142 145 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 622 625 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1298 1301 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
One needs to be cognizant of an important point with regards to the interpretation of our results. The genetic variations in CCR5 that affect HIV disease course differ in European and African Americans [18], [56], and the average copy number of CCL3L1 varies among populations [5]. Thus, we caution that as the genetic information was derived from European and African American HIV-positive subjects and because host-virus interactions are likely to be highly population-specific, the composition of the GRGs might vary depending on the study population. Despite this caveat, it is noteworthy that the impact of CCL3L1 on HIV-AIDS susceptibility has been observed in different geographic regions ([5], [43], [44], [45], [46] and unpublished observations), and that we and others have found reproducible effects of specific CCR5 haplotype pairs on disease progression rates (e.g. detrimental and beneficial impact of the CCR5 HHE/HHE and HHC/HHG*2 genotypes, respectively [15], [17], [18], [19], [39]). Illustrating a basis for the consistency of the disease-influencing associations, these CCR5 haplotypes are also associated with increased (CCR5-HHE) or decreased (HHC or HHG*2) gene/protein expression of CCR5 [39], [68], [69], [70], [71], and of note, CCR5 density is in itself a determinant of HIV susceptibility [69], [72], viral load [73], disease progression rates [74], and CD4 recovery during HAART [75], [76].
###end p 75
###begin p 76
###xml 699 710 699 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 840 844 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mangano1">[19]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 852 856 852 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 931 934 931 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lederman1">[1]</xref>
###xml 1348 1352 1348 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Taub1">[77]</xref>
###xml 1354 1358 1354 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Karpus1">[78]</xref>
###xml 1360 1364 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Zou1">[79]</xref>
###xml 1366 1370 1366 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Pinto1">[80]</xref>
###xml 1372 1376 1372 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Luther1">[81]</xref>
###xml 1378 1382 1378 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Abdelwahab1">[82]</xref>
###xml 1384 1388 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lillard1">[83]</xref>
###xml 1390 1394 1390 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Rot1">[84]</xref>
###xml 1396 1400 1396 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Molon1">[85]</xref>
###xml 1402 1406 1402 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Castellino1">[86]</xref>
###xml 1408 1412 1408 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Friedman1">[87]</xref>
###xml 1414 1418 1414 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lin1">[88]</xref>
###xml 1420 1424 1420 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Amella1">[89]</xref>
###xml 1426 1430 1426 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Tyner1">[90]</xref>
###xml 1488 1499 1488 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1621 1632 1621 1632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1759 1762 1759 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Gonzalez1">[5]</xref>
###xml 1764 1768 1764 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 1770 1774 1770 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Ahuja1">[23]</xref>
###xml 2023 2029 2023 2029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1</italic>
###xml 2046 2050 2046 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 93 96 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 916 919 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1196 1199 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1530 1533 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1646 1649 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1712 1715 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
These findings also have value for improving our understanding of the factors that influence HIV-AIDS pathogenesis and for the interpretation of genotype-phenotype association studies in general. The ability of the GRGs to provide an additive measure of AIDS risk, including in those with high CD4 cell counts, suggests that the impact of these host factors during chronic infection is partly through viral load-independent mechanisms that are likely operative in the proximal end of the causal pathways that affect CD4 cell loss and establishment of the steady-state viral load. This inference is consistent with those derived from the results our previous studies where we suggested that a common CCL3L1-CCR5 genetic pathway may regulate the balance between pathogenic and reparative processes from the early stages of the disease course [19], [20], [23]. These findings suggest that in addition to their roles in HIV cell entry [1], CCR5 and its ligands may also influence disease pathogenesis by impacting on parameters that are not dependent on viral entry. This is consistent with the observation that CCR5 and its ligands associate with a wide array of immunological responses relevant to HIV-AIDS pathogenesis, including cell-mediated immunity, T cell regeneration, activation-induced cell death, and formation of the immunological synapse [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90]. However, it is likely that the relative impact of these CCL3L1-CCR5-dependent immune responses on HIV-AIDS pathogenesis may differ depending on disease stage. Furthermore, the influence of CCL3L1-CCR5 genotypes on HIV-AIDS pathogenesis is evident at time of viral exposure (i.e., HIV acquisition) and soon after seroconversion [5], [20], [23], and as shown herein, these genetic factors provide independent prognostic information from the early stages of the disease. Hence, from an epidemiological standpoint the aforementioned observations suggest that genotype-phenotype associations for CCL3L1 copy number and CCR5 genotype may differ significantly depending on the characteristics and disease stage of the subjects evaluated (e.g., those enrolled from the early stages of their infection as part of a natural history cohort versus accrual of subjects during the later stages of disease, or those enrolled as part of a clinical trial, or selection of subjects based on specific clinical or laboratory characteristics).
###end p 76
###begin p 77
###xml 212 223 212 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 351 355 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Dolan1">[20]</xref>
###xml 510 511 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 524 528 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Rodriguez1">[91]</xref>
###xml 557 568 533 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 1011 1015 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Mayer1">[92]</xref>
###xml 1047 1051 1023 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003165-Lalezari1">[93]</xref>
###xml 1103 1104 1079 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The notion that a large component of AIDS pathogenesis might be conveyed by parameters that are independent of the viral load is suggested by our previous findings where we found that steady-state viral load and CCL3L1-CCR5 GRG status each explained approximately9% and approximately6%, respectively, of the variability in rate of progression to AIDS [20]. The studies by Rodriguez et al also underscore the notion that viral load only explains a small fraction of the variability in the rate of decline in CD4+ cell counts [91]. Thus, the finding that the CCL3L1-CCR5 GRGs influence AIDS pathogenesis partly independent of the viral load suggests that strategies to block viral load-independent pathways, such as those linked to the CCL3L1-CCR5 axis, might provide a novel means to curb CD4 cell loss during infection and aid immune reconstitution. Whether this can be accomplished with the current generation of CCR5 blockers needs to be carefully evaluated because studies with a small molecule CCR5 blocker [92] and a CCR5 monoclonal antibody [93] suggest a beneficial effect of blocking CCR5 on CD4+ T cell recovery during HAART, in instances when the prevailing viral strain is X4-tropic and independent of viral load suppression, respectively.
###end p 77
###begin p 78
###xml 292 299 292 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 711 722 711 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL3L1-CCR5</italic>
###xml 724 727 724 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 158 161 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 237 242 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 586 589 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 778 781 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 950 953 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1138 1146 <span type="species:ncbi:9606">patients</span>
In summary, we have conducted proof-of-concept analyses to determine whether genetic information can be used to bring us one step closer towards personalized HIV medicine. Using several different approaches, in this prospective study of HIV-1 infected individuals, the predictive capacity of CCL3L1- and CCR5-based genetic risk stratification was not only independent of, but more importantly, comparable to the prognostic information provided by currently used predictors of AIDS risk. Thus, additional studies will be required to determine whether in a manner analogous to the use of HIV genotype, when applied judiciously along with knowledge of the clinical and laboratory parameters, host genotypes (e.g., CCL3L1-CCR5, HLA alleles) that associate with different aspects of HIV disease pathogenesis, independent of CD4 cell count and viral load, might have practical utility in guiding the care of infected individuals. Of broad relevance, using HIV as a model system, we outline a series of analyses that might have application to other diseases when assessing whether genetic information can be used to improve the clinical care of patients afflicted with these diseases.
###end p 78
###begin title 79
Supporting Information
###end title 79
###begin p 80
Supplemental Online Materials - Text
###end p 80
###begin p 81
(0.07 MB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Classification trees and their clinical application in the HIV+ WHMC cohort.
###end p 83
###begin p 84
(0.35 MB TIF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Replication of results of CART analysis in the seroprevalent component of the WHMC HIV+ cohort.
###end p 86
###begin p 87
(0.31 MB TIF)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
(0.04 MB DOC)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin p 91
We thank S. Wegner and other members of IDCRP for critical support of this work; P. Melby for invaluable programmatic support at UTHSCSA; M. Mamtani and E. Wright for critical reading of the manuscript; S. Anderson, R. Sanchez for technical help; B. Shah for outstanding dedication to the graphic work; and A. S. Ahuja for forbearance. We are indebted to the subjects who enrolled in these studies and who made this work possible. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting the views of the Departments of the Army, Navy, Air Force, or the Department of Defense. HK dedicates this paper to the memory of his mother, Mrs. Lata R. Kulkarni (02/26/1931-01/14/2006).
###end p 91
###begin title 92
References
###end title 92
###begin article-title 93
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Biology of CCR5 and its role in HIV infection and treatment.
###end article-title 93
###begin article-title 94
###xml 49 54 <span type="species:ncbi:9606">human</span>
Gene copy number regulates the production of the human chemokine CCL3-L1.
###end article-title 94
###begin article-title 95
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.
###end article-title 95
###begin article-title 96
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha.
###end article-title 96
###begin article-title 97
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.
###end article-title 97
###begin article-title 98
###xml 49 52 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 154 157 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
###end article-title 98
###begin article-title 99
###xml 20 23 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
###end article-title 99
###begin article-title 100
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The case for earlier treatment of HIV infection.
###end article-title 100
###begin article-title 101
Antiretroviral therapy: the "when to start" debates.
###end article-title 101
###begin article-title 102
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.
###end article-title 102
###begin article-title 103
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 125 128 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
###end article-title 103
###begin article-title 104
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
###end article-title 104
###begin article-title 105
Genetic acceleration of AIDS progression by a promoter variant of CCR5.
###end article-title 105
###begin article-title 106
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genes that limit AIDS.
###end article-title 106
###begin article-title 107
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Influence of host genetic variation on susceptibility to HIV type 1 infection.
###end article-title 107
###begin article-title 108
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes.
###end article-title 108
###begin article-title 109
###xml 129 137 <span type="species:ncbi:9606">children</span>
###xml 161 189 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.
###end article-title 109
###begin article-title 110
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
###end article-title 110
###begin article-title 111
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
###end article-title 111
###begin article-title 112
###xml 29 32 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Host genetic determinants of HIV pathogenesis: an immunologic perspective. Immune correlates of protection, activation and exhaustion.
###end article-title 112
###begin article-title 113
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.
###end article-title 113
###begin article-title 114
The influence of HLA genotype on AIDS.
###end article-title 114
###begin article-title 115
###xml 50 78 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Host factors associated with outcome from primary human immunodeficiency virus-1 infection.
###end article-title 115
###begin article-title 116
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
T cell dynamics in HIV-1 infection.
###end article-title 116
###begin article-title 117
###xml 101 104 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
###end article-title 117
###begin article-title 118
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.
###end article-title 118
###begin article-title 119
###xml 86 93 <span type="species:ncbi:9606">persons</span>
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
###end article-title 119
###begin article-title 120
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.
###end article-title 120
###begin article-title 121
Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy.
###end article-title 121
###begin article-title 122
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
###end article-title 122
###begin article-title 123
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.
###end article-title 123
###begin article-title 124
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.
###end article-title 124
###begin article-title 125
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
###end article-title 125
###begin article-title 126
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
###end article-title 126
###begin article-title 127
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS).
###end article-title 127
###begin article-title 128
###xml 129 164 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
###end article-title 128
###begin article-title 129
Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.
###end article-title 129
###begin article-title 130
Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.
###end article-title 130
###begin article-title 131
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 102 107 <span type="species:ncbi:9606">human</span>
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
###end article-title 131
###begin article-title 132
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User. 15th Conference on Retroviruses and Opportunistic Infections.
###end article-title 132
###begin article-title 133
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 95 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia.
###end article-title 133
###begin article-title 134
###xml 8 15 <span type="species:ncbi:9606">infants</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
###end article-title 134
###begin article-title 135
###xml 101 131 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission.
###end article-title 135
###begin article-title 136
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 122 127 <span type="species:ncbi:9606">women</span>
Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women.
###end article-title 136
###begin article-title 137
Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity.
###end article-title 137
###begin article-title 138
Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the U.S.A.
###end article-title 138
###begin article-title 139
###xml 90 93 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research.
###end article-title 139
###begin article-title 140
###xml 73 101 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group.
###end article-title 140
###begin article-title 141
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 167 195 <span type="species:ncbi:12721">human immunodeficiency virus</span>
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus.
###end article-title 141
###begin article-title 142
###xml 58 93 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro.
###end article-title 142
###begin article-title 143
###xml 46 60 <span type="species:ncbi:9544">rhesus macaque</span>
Evolutionary and biomedical insights from the rhesus macaque genome.
###end article-title 143
###begin article-title 144
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
###end article-title 144
###begin article-title 145
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.
###end article-title 145
###begin article-title 146
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.
###end article-title 146
###begin article-title 147
Effectiveness of highly-active antiretroviral therapy by race/ethnicity.
###end article-title 147
###begin article-title 148
Clinical utility of likelihood ratios.
###end article-title 148
###begin article-title 149
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Decision rule and utility of routine urine toxicology screening of trauma patients.
###end article-title 149
###begin article-title 150
Classification and regression tree analysis in public health: methodological review and comparison with logistic regression.
###end article-title 150
###begin article-title 151
Selecting pre-screening items for early intervention trials of dementia-a case study.
###end article-title 151
###begin article-title 152
Classification methods for confronting heterogeneity.
###end article-title 152
###begin article-title 153
A novel approach toward development of a rapid blood test for breast cancer.
###end article-title 153
###begin article-title 154
###xml 89 102 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 128 156 <span type="species:ncbi:12721">human immunodeficiency virus</span>
The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.
###end article-title 154
###begin article-title 155
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
###end article-title 155
###begin article-title 156
###xml 15 44 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
###end article-title 156
###begin article-title 157
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 279 284 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 289 318 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.
###end article-title 157
###begin article-title 158
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 81 84 <span type="species:ncbi:9606">men</span>
###xml 103 106 <span type="species:ncbi:9606">men</span>
CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men.
###end article-title 158
###begin article-title 159
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.
###end article-title 159
###begin article-title 160
###xml 3 6 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms.
###end article-title 160
###begin article-title 161
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infection.
###end article-title 161
###begin article-title 162
###xml 74 81 <span type="species:ncbi:9606">persons</span>
###xml 96 131 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1.
###end article-title 162
###begin article-title 163
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression.
###end article-title 163
###begin article-title 164
###xml 111 146 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Response to treatment and disease progression linked to CD4+ T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection.
###end article-title 164
###begin article-title 165
The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 density.
###end article-title 165
###begin article-title 166
###xml 71 76 <span type="species:ncbi:9606">human</span>
Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro.
###end article-title 166
###begin article-title 167
Differential CC chemokine-induced enhancement of T helper cell cytokine production.
###end article-title 167
###begin article-title 168
Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12.
###end article-title 168
###begin article-title 169
###xml 69 72 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Beta-chemokines inhibit activation-induced death of lymphocytes from HIV-infected individuals.
###end article-title 169
###begin article-title 170
Chemokines as regulators of T cell differentiation.
###end article-title 170
###begin article-title 171
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses.
###end article-title 171
###begin article-title 172
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity.
###end article-title 172
###begin article-title 173
Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells.
###end article-title 173
###begin article-title 174
T cell costimulation by chemokine receptors.
###end article-title 174
###begin article-title 175
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.
###end article-title 175
###begin article-title 176
Surface-bound chemokines capture and prime T cells for synapse formation.
###end article-title 176
###begin article-title 177
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection.
###end article-title 177
###begin article-title 178
###xml 67 102 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP.
###end article-title 178
###begin article-title 179
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection.
###end article-title 179
###begin article-title 180
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 84 87 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
###end article-title 180
###begin article-title 181
###xml 219 224 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial.
###end article-title 181
###begin article-title 182
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 122 127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
###end article-title 182
###begin p 183
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 183
###begin p 184
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 88 91 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Funding: This work was supported by the Veterans Administration (VA) Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) and other awards (AI043279 and MH069270) from the NIH to S.K.A. S.K.A. is a recipient of the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. Support for the Wilford Hall Medical Center cohort was provided by the Infectious Disease Clinical Research Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS), of which the Tri-Service AIDS Clinical Consortium (TACC) is a component. The IDCRP is a Department of Defense tri-service program executed through USUHS and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), in collaboration with HHS/NIH/NIAID/DCR through Interagency Agreement HU0001-05-2-0011. The authors have no commercial or other association that might pose a conflict of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 184

